The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Open accessAbstract
PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The objective response rate was 69%, and the disease control rate was 84%; there was a 13% complete response rate. Median progression-free survival and overall survival had not been met at 24.2 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [80]
In the citing paper
“in addition to the already established effectiveness of this combination in primary dMMR/MSI-H and second or later line treatment of dMMR/MSI-H mCRC.105 106”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [106]
In the citing paper
“However, despite the high rate of durable responses, a fraction of them will develop immune resistance that can outweigh prolonged survival outcomes (approximately 15–29%) [12,15,16].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationAntonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Colorectal Cancer Incidence Patterns in the United States, 1974–2013
Siegel, R. L., Fedewa, S. A., Anderson, W. F., Miller, K. D., Ma, J., Rosenberg, P. S., & Jemal, A. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw322 · Cited by 1,002
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. F. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 932
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H. M., Callahan, M. K., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 473
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317
Self-citationDiaz, L. A., Marabelle, A., Delord, J., Shapira‐Frommer, R., Geva, R., Peled, N., Kim, T. W., André, T., Cutsem, E. V., Guimbaud, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3071 · Cited by 125
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
Rieth, J. M., & Subramanian, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051340 · Cited by 92
Janjigian, Y. Y., Ott, P. A., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Peltola, K. J., Jaeger, D., Evans, T. R. J., de Braud, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4014 · Cited by 71
Marginean, E. C., & Melosky, B. L. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0041-ra · Cited by 39
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.635 · Cited by 38
Self-citationTougeron, D., Cohen, R., Sueur, B., Sefrioui, D., Gentilhomme, L., Lecomte, T., Aparicio, T., Guetz, G. D., Artru, P., de la Fouchardière, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.059 · Cited by 15
Heinemann, V., Kraemer, N., Buchner, H., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3591 · Cited by 15
Flagged first, then by citations
Research works printed but not linked: 3
- 2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
- National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
- National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)
Cited by
Sorted by citations
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 717
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Qing, T., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 580
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
Chalabi, M., Verschoor, Y. L., Tan, P. B., Balduzzi, S., van Lent, A. U., Grootscholten, C., Dokter, S., Büller, N. V. J. A., Grotenhuis, B. A., Kuhlmann, K. F. D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400634 · Cited by 541
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12516 · Cited by 470
Metadata
- Authors
- Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
- Affiliations
- USC Norris Comprehensive Cancer Center (US)
- University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
- Hospital Universitario Virgen del Rocio, Sevilla, Spain
- Westmead Hospital (AU)
- Institut Jules Bordet (BE)
- Candiolo Cancer Institute (IT)
- Hospital General Universitario Gregorio Marañón (ES)
- Universitair Ziekenhuis Brussel (BE)
- University of Modena and Reggio Emilia (IT)
- Vanderbilt University (US)
- Banner MD Anderson Cancer Center (US)
- Lehigh Valley Cancer Institute, Allentown, PA
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Istituto Oncologico Veneto (IT)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2022-01-10
- Volume
- 40
- Issue
- 2
- Pages
- 161-170
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3206775306
- Semantic Scholar
- 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
- Cited by
- 728
- References
- 30
- Citations by year
- 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
- FWCI
- 41.26
- Type
- journal article
- Language
- en
- Open access
- green
- biblio.vub.ac.be
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Agilent Technologies (PD-L1 IHC 28-8)
- Ono Pharmaceutical
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
- MeSH terms
- Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
